In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176 Manabu TakagiTakuya HonmuraHiroyoshi Hidaka OriginalPaper Pages: 387 - 399
Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin A. BergamoL. MessoriG. Sava OriginalPaper Pages: 401 - 411
Quinolizidinyl derivatives of iminodibenzyl and phenothiazine as multidrug resistance modulators in ovarian cancer cells Federica BarbieriAngela AlamaFabio Sparatore OriginalPaper Pages: 413 - 420
Effect of novel benzoylphenylurea derivatives on DNA polymerase α activity using the synthesome-based in vitro model system Waleed Abdel-AzizRobert HickeyLinda Malkas OriginalPaper Pages: 421 - 428
A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors Susan M. ChangJohn G. KuhnMichael D. Prados OriginalPaper Pages: 429 - 433
Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism Albert FontJosé Miguel SánchezRafael Rosell OriginalPaper Pages: 435 - 443
Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies Robert WiederSteven C. NovickSteven Soignet OriginalPaper Pages: 445 - 452
A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study Deborah K. ArmstrongJohn A. BlessingJoel I. Sorosky OriginalPaper Pages: 453 - 457
Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes Rosa SánchezEmilio EstebanAngel J. Lacave OriginalPaper Pages: 459 - 463
A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer Maha HussainUlka VaishampayanLawrence Flaherty OriginalPaper Pages: 465 - 471
A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma Karl BélangerDavid MacDonaldElizabeth Eisenhauer OriginalPaper Pages: 473 - 480
An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma Peter ReichardtKarin OechsleJörg Thomas Hartmann OriginalPaper Pages: 481 - 486